platinum has been researched along with apatinib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gourley, C | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S | 1 |
| Chen, Y; He, H; Li, L; Luo, Z; Pan, Z; Yang, Z; Zhao, B | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
| Cai, XY; Chen, QY; Deng, SW; Guo, L; Guo, SS; Jia, GD; Li, SC; Li, XY; Li, YF; Lin, DF; Liu, LT; Liu, SL; Luo, DH; Lv, XF; Mai, HQ; Sun, XS; Tang, LQ; Xie, SY; Yuan, L; Zeng, MS | 1 |
2 trial(s) available for platinum and apatinib
| Article | Year |
|---|---|
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immune Checkpoint Inhibitors; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platinum | 2023 |
3 other study(ies) available for platinum and apatinib
| Article | Year |
|---|---|
Apatinib and etoposide: surprising efficacy of an oral combination.
Topics: Etoposide; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Pyridines | 2018 |
Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Platinum; Prognosis; Pyridines; Retrospective Studies; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |